An official website of the United States government
Pain
Topics
Validation of a Community Pharmacy-based Prescription Drug Monitoring Program Risk Screening Tool (PHARMSCREEN) (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative®
The primary objective of this study is to evaluate the criterion and concurrent validity of the Narcotic Score (NS metric) as a clinical measure of opioid misuse and use disorder and establish risk level thresholds within community pharmacies - an optimal - yet underutilized setting for identification and engagement of patients with opioid risk.
Gerald Cochran, MSW, Ph.D.
Associate Professor
University of Utah Health
383 Colorow Way, Mailbox 16, Salt Lake City, UT, 84108, US
Innovatively Increasing PCP Prescribing of Buprenorphine: Measurement Based Care and Integrated Electronic Solution (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative®
Medication Treatment for Opioid-dependent Expecting Mothers (MOMs): A Pragmatic Randomized Trial Comparing Two Buprenorphine Formulations (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative®
Developing a Prescription Opioid Registry across Diverse Health Systems (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative®
The goal of the proposed study is to expand the prescription opioid registry developed in study CTN 0061, across diverse health systems with harmonized EHR data, and leverage it to answer several key ‘next step’ research questions in response to the opioid crisis. We propose to adapt and expand the registry to 8 other health systems across the nation, initially within the Health System Node (HSN) to maximize efficiency in the short study timeframe, but with potential to be expanded to other nodes in the future.
A Foundation to Examine Reasons for Discontinuation for Buprenorphine Care in the Veterans Health Administration (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative®
This study will include analyses of VA databases to examine patient and organizational characteristics associated with buprenorphine termination during outpatient treatment for opioid use disorder. These analyses are critical for generating data and forming further hypotheses on how to implement targeted approaches to improve retention in treatment.
Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO
Professor of Medicine and Psychiatry
University of Utah Health
Inpatient versus Outpatient Treatment Outcomes for People with Opioid Use Disorder (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative®
This study will use a multi-state linked administrative database to compare opioid-related outcomes among Medicaid recipients admitted for treatment of opioid use disorder in outpatient and inpatient (or residential) facilities. Patient and organizational factors predicting higher retention in outpatient treatment for OUD will also be examined. These data will be used to generate hypotheses on how to improve retention in treatment.
Dan Hartung, PharmD, MPH
Associate Professor
Individual Level Predictive Modeling of Opioid Use Disorder Treatment Outcome (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative®
This project will develop models to predict individual patient’s risk for relapse (or dropout from treatment) when treated with medications for OUD including methadone, buprenorphine, or extended-release depot naltrexone.
Sean Luo, MD, Ph.D.
Assistant Professor
Columbia University
1051 Riverside Drive, Unit 66, New York, NY, 10033, US
Collaborative Care for Polysubstance use in Primary Care Settings (Co-Care) (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative®
Determining the Optimal Duration of Buprenorphine Treatment to Reduce the Risk of Relapse, Overdose, and Mortality (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative®
Integrating pharmacy-based prevention and treatment of opioid and other substance use disorders: A survey of pharmacists and stakeholder (NIH HEAL Initiative)
Funded by the NIH HEAL Initiative®
This study will use mixed methods to study pharmacists’ knowledge of, attitudes about, and intention to provide patient care and services for Screening for substance use, Brief Intervention, and Referral to Treatment (SBIRT) for substance use disorders (SUDs) and Medication treatment for Opioid Use Disorders (MOUD). The findings will inform barriers and facilitators related to pharmacist-provided services and patient care for SBIRT and MOUD. A survey instrument for assessing such barriers and facilitators will be developed.